This is the third time you've posted the same article trying to claim that the "SUCCEED is an "all comers" trial....all sarcomas are being thrown into the bucket..." However, repeating something again and again doesn't make it any more true.
I'll try to make this simple. 1) Not all sarcoma's respond equally to chemotherapy. 2) Patients with sarcomas that do respond to chemo were much more likely to end up in the P3 trial. 3) Consequently, the premise underlying your "pick one" "50/50" argument is fundamentally flawed. I hope this puts this canard to rest.
ps have you figured out which of the sarcoma subtypes respond best to chemo yet? Here's a clue for you, they just happen to be the same ones, like leiomyosarcomas, that had the higher response rates in the P2 but I'm sure that was just a coincidence and wasn't factored into the P3 trial design at all....yeah, right.
News 
Market Data 
Discover 
